A 2-year review of publicly funded cell-free DNA screening in Ontario: utilization and adherence to funding criteria

被引:11
作者
Bellai-Dussault, Kara [1 ,2 ]
Meng, Lynn [1 ]
Huang, Tianhua [1 ,3 ,4 ,5 ]
Reszel, Jessica [1 ,2 ]
Walker, Mark [1 ,2 ,6 ,7 ]
Lanes, Andrea [1 ]
Okun, Nan [1 ,8 ]
Armour, Christine [1 ,2 ,9 ]
Dougan, Shelley [1 ,2 ]
机构
[1] Better Outcomes Registry & Network BORN Ontario, Ottawa, ON, Canada
[2] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada
[3] North York Gen Hosp, Toronto, ON, Canada
[4] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[5] Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada
[6] Ottawa Hosp, Ottawa, ON, Canada
[7] Ottawa Hosp, Res Inst OHRI, Ottawa, ON, Canada
[8] Mt Sinai Hosp, Toronto, ON, Canada
[9] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada
关键词
FREE FETAL DNA; DOWN-SYNDROME; ANEUPLOIDY; IMPLEMENTATION; PERFORMANCE; TRISOMY-21; DIAGNOSIS; WOMEN; COST; NIPT;
D O I
10.1002/pd.5563
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective Ontario offers a publicly funded modified contingent model of prenatal screening for aneuploidy in which cell-free DNA (cfDNA) screening is covered for pregnancies at higher risk of fetal aneuploidy. The objective of this study was to review utilization of provincially funded cfDNA screening and adherence to the criteria laid out in Ontario prenatal screening guidelines. Methods This was a descriptive cohort study using data collected by Ontario's prescribed maternal and child registry. The study population included all pregnant individuals who received cfDNA screening from January 2016 to December 2017. Results The most common criteria for provincially funded cfDNA screening were advanced maternal age >= 40 years (37.7%), positive multiple marker screen (34.1%), modifying risk factors such as ultrasound soft markers (7.1%), and previous aneuploidy (5.5%). The audit demonstrated that 2.9% of funded cfDNA screens tests did not meet funding criteria, and that 11.4% of self-paid cfDNA screens could have been publicly funded. Conclusion Reviewing and auditing the application of criteria for funded cfDNA screening using prescribed registry data allows an opportunity to identify areas where targeted education may improve adherence to standardized screening protocols, and provides a basis for reassessment of the funding model.
引用
收藏
页码:164 / 172
页数:9
相关论文
共 35 条
[1]   Non-invasive prenatal testing: a review of international implementation and challenges [J].
Allyse, Megan ;
Minear, Mollie A. ;
Berson, Elisa ;
Sridhar, Shilpa ;
Rote, Margaret ;
Hung, Anthony ;
Chandrasekharan, Subhashini .
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 :113-126
[2]  
[Anonymous], 2016, SAS SOFTW
[3]  
Audibert F, 2017, J OBSTET GYNAECOL CA, V39, P805, DOI 10.1016/j.jogc.2017.01.032
[4]  
*BC PREN GEN SCREE, 2019, ORD FUND NON PREN TE
[5]   The value of non-invasive prenatal testing: preferences of Canadian pregnant women, their partners, and health professionals regarding NIPT use and access [J].
Birko, Stanislav ;
Ravitsky, Vardit ;
Dupras, Charles ;
Le Clerc-Blain, Jessica ;
Lemoine, Marie-Eve ;
Affdal, Aliya O. ;
Haidar, Hazar ;
Laberge, Anne-Marie .
BMC PREGNANCY AND CHILDBIRTH, 2019, 19 (1)
[6]  
*BORN ONT, 2019, BORN
[7]   Obstetrical provider knowledge and attitudes towards cell-free DNA screening: results of a cross-sectional national survey [J].
Chan, Wilson V. ;
Johnson, Jo-Ann ;
Wilson, R. Douglas ;
Metcalfe, Amy .
BMC PREGNANCY AND CHILDBIRTH, 2018, 18
[8]   Maternal age trends support uptake of non-invasive prenatal testing (NIPT) in the low-risk population [J].
Chen, Kelly M. ;
White, Karen ;
Shabbeer, Junaid ;
Schmid, Maximilian .
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2019, 32 (23) :4039-4042
[9]   Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening [J].
Chetty, Shilpa ;
Garabedian, Matthew J. ;
Norton, Mary E. .
PRENATAL DIAGNOSIS, 2013, 33 (06) :542-546
[10]  
*CTR MED GEN, 2018, PREN EX NIPT